Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.25
- Piotroski Score 2.00
- Grade Buy
- Symbol (APRE)
- Company Aprea Therapeutics, Inc.
- Price $2.75
- Changes Percentage (-0%)
- Change -$0
- Day Low $2.60
- Day High $2.85
- Year High $8.85
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.28
- Trailing P/E Ratio -1.37
- Forward P/E Ratio -1.37
- P/E Growth -1.37
- Net Income $-14,286,756
Income Statement
Quarterly
Annual
Latest News of APRE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
Aprea Therapeutics' cash burn analysis shows a decent cash runway with reduced burn rate. Despite low revenue, the company's financial prudence is improving. However, its high expenditure relative to ...
By Yahoo! Finance | 2 months ago